NCT02578914Phase 2Completed

A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

Study sponsor: Aldeyra Therapeutics, Inc. · ALDX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2015-12Actual
Enrollment · participants100Actual
Source updated2023-12-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.